FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046977319> ?p ?o ?g. }

• W2046977319 endingPage "104" @default.
• W2046977319 startingPage "93" @default.
• W2046977319 abstract "N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (PK1) is a novel polymeric anticancer agent containing doxorubicin (approximately 8 wt%) bound to the polymer backbone via a Gly-Phe-Leu-Gly peptidyl linker. The approximate LD 50 of PK1 in MF1 mice after a single i.v. injection was 63 mg/kg (doxorubicin-equivalent). Single doses of PK1 were administered to MF1 mice at 22.5 or 45 mg/kg and blood samples taken on days 3, 7 and 14 for haematological examination and clinical chemistry. At day 14 all animals were sacrificed for necropsy. In a multiple dose study, PK1 was administered i.v. to MF1 mice or Wistar rats (20 animals per group) weekly for five consecutive weeks at doses of 12.0 or 22.5 mg/kg (mice) or 3 and 5 mg/kg (rats). After 31 days 10 animals from each group were sacrificed for necropsy and the remainder were sacrificed after 59 days. Blood samples were taken 3 days after administration of each dose and at the end of the experiment, and urine samples were collectedonthe day prior to sacrifice.Mortality inthe single dose mouse and multiple dose rat studies was low. In the multiple dose mouse study 4/10 animals were killed in extremis before the scheduled day 31 and all animals died before day 37. PK1 induced a reduction in WBC and platelets in rats and mice shortly after treatment and RBC at later times, and in the single dose study alanine and aspartate aminotransferase levels were elevated at higher doses. Liver damage was seen only in rat tissue during histological examination. Other histological changes induced by PK1 include thymic and testicular atrophy, bone marrow depletion gastrointestinal tract changes and in the multiple dose study an increase in nuclear size in the proximal tubules of the kidney (although no changes in urine were seen). Recovery from these effects was seen in rats at 59 days. A PK1 dose of 20 mg/m 2 (doxorubicin equivalent) was recommended as a safe dose for the start of Phase I clinical trials." @default.
• W2046977319 created "2016-06-24" @default.
• W2046977319 creator A5040979364 @default.
• W2046977319 creator A5046042625 @default.
• W2046977319 creator A5064892508 @default.
• W2046977319 date "1998-02-01" @default.
• W2046977319 modified "2023-09-27" @default.
• W2046977319 title "Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)" @default.
• W2046977319 cites W1830217992 @default.
• W2046977319 cites W1964455520 @default.
• W2046977319 cites W1979851400 @default.
• W2046977319 cites W1984557808 @default.
• W2046977319 cites W1986844753 @default.
• W2046977319 cites W2005408885 @default.
• W2046977319 cites W2011008013 @default.
• W2046977319 cites W2021743881 @default.
• W2046977319 cites W2022361916 @default.
• W2046977319 cites W2032445130 @default.
• W2046977319 cites W2045460706 @default.
• W2046977319 cites W2059212524 @default.
• W2046977319 cites W2065910438 @default.
• W2046977319 cites W2071008344 @default.
• W2046977319 cites W2079859890 @default.
• W2046977319 cites W2088501009 @default.
• W2046977319 cites W2092639730 @default.
• W2046977319 cites W2157166246 @default.
• W2046977319 cites W2321195922 @default.
• W2046977319 cites W4229765017 @default.
• W2046977319 cites W4248817696 @default.
• W2046977319 doi "https://doi.org/10.1177/096032719801700204" @default.
• W2046977319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9506260" @default.
• W2046977319 hasPublicationYear "1998" @default.
• W2046977319 type Work @default.
• W2046977319 sameAs 2046977319 @default.
• W2046977319 citedByCount "22" @default.
• W2046977319 countsByYear W20469773192012 @default.
• W2046977319 countsByYear W20469773192013 @default.
• W2046977319 countsByYear W20469773192015 @default.
• W2046977319 countsByYear W20469773192016 @default.
• W2046977319 countsByYear W20469773192017 @default.
• W2046977319 countsByYear W20469773192021 @default.
• W2046977319 crossrefType "journal-article" @default.
• W2046977319 hasAuthorship W2046977319A5040979364 @default.
• W2046977319 hasAuthorship W2046977319A5046042625 @default.
• W2046977319 hasAuthorship W2046977319A5064892508 @default.
• W2046977319 hasConcept C126322002 @default.
• W2046977319 hasConcept C185592680 @default.
• W2046977319 hasConcept C2776694085 @default.
• W2046977319 hasConcept C2781303535 @default.
• W2046977319 hasConcept C29730261 @default.
• W2046977319 hasConcept C71924100 @default.
• W2046977319 hasConcept C98274493 @default.
• W2046977319 hasConceptScore W2046977319C126322002 @default.
• W2046977319 hasConceptScore W2046977319C185592680 @default.
• W2046977319 hasConceptScore W2046977319C2776694085 @default.
• W2046977319 hasConceptScore W2046977319C2781303535 @default.
• W2046977319 hasConceptScore W2046977319C29730261 @default.
• W2046977319 hasConceptScore W2046977319C71924100 @default.
• W2046977319 hasConceptScore W2046977319C98274493 @default.
• W2046977319 hasIssue "2" @default.
• W2046977319 hasLocation W20469773191 @default.
• W2046977319 hasLocation W20469773192 @default.
• W2046977319 hasOpenAccess W2046977319 @default.
• W2046977319 hasPrimaryLocation W20469773191 @default.
• W2046977319 hasRelatedWork W1973847438 @default.
• W2046977319 hasRelatedWork W2093442802 @default.
• W2046977319 hasRelatedWork W2328504369 @default.
• W2046977319 hasRelatedWork W2397482356 @default.
• W2046977319 hasRelatedWork W2404849105 @default.
• W2046977319 hasRelatedWork W3209127409 @default.
• W2046977319 hasRelatedWork W56377649 @default.
• W2046977319 hasRelatedWork W89677992 @default.
• W2046977319 hasRelatedWork W2185582915 @default.
• W2046977319 hasRelatedWork W2301260833 @default.
• W2046977319 hasVolume "17" @default.
• W2046977319 isParatext "false" @default.
• W2046977319 isRetracted "false" @default.
• W2046977319 magId "2046977319" @default.
• W2046977319 workType "article" @default.